Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies—Taming T REX

Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies—Taming T REX Opinion EDITORIAL Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies—Taming T REX William Damsky, MD, PhD; Brett A. King, MD, PhD Targeted, or pathogenesis-based, therapies are revolutioniz- Figure. Overview of JAK-STAT Signaling in Dermatologic Disorders ing medicine. For the past decade and a half, as science has honed in on the primary events in psoriasis pathogenesis, treat- Atopic Alopecia Inerferon- Psoriasis Dermatitis Areata opathies ment has evolved from that of a hammer to that of a laser. The IL-12 IL-4 IFN-γ IFN-α discovery that helper T-cell IL-23 IL-13 IL-15 IFN-β subtype 17 (TH17) immunity Related article page 342 (and related cytokines inter- leukin-17 [IL-17] and IL-23) plays a central role in psoriasis JAK2/TYK2 JAK1/3 JAK1/2 JAK1/TYK2 JAK pathogenesis has led to the development of effective treat- JAK2/TYK2 JAK1/TYK2 JAK1/3 JAK1/TYK2 inhibitor ments with agents targeting IL-17 and IL-23 (eg, secukinumab and guselkumab, respectively). More recently our understand- STAT activation STAT activation STAT activation STAT activation ing of atopic dermatitis pathogenesis has advanced and we now Disease Disease Disease Disease have targeted therapy for this common dermatosis. The cyto- pathogenesis pathogenesis pathogenesis pathogenesis kines IL-4 and IL-13 have been identified as drivers of atopic IL indicates interleukin; JAK, Janus http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Dermatology American Medical Association

Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies—Taming T REX

JAMA Dermatology , Volume 155 (3) – Mar 23, 2019

Loading next page...
 
/lp/american-medical-association/targeted-treatment-of-trex1-chilblain-lupus-and-other-P1ag96Yxmi
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2168-6068
eISSN
2168-6084
DOI
10.1001/jamadermatol.2018.4836
Publisher site
See Article on Publisher Site

Abstract

Opinion EDITORIAL Targeted Treatment of TREX1 Chilblain Lupus and Other Interferonopathies—Taming T REX William Damsky, MD, PhD; Brett A. King, MD, PhD Targeted, or pathogenesis-based, therapies are revolutioniz- Figure. Overview of JAK-STAT Signaling in Dermatologic Disorders ing medicine. For the past decade and a half, as science has honed in on the primary events in psoriasis pathogenesis, treat- Atopic Alopecia Inerferon- Psoriasis Dermatitis Areata opathies ment has evolved from that of a hammer to that of a laser. The IL-12 IL-4 IFN-γ IFN-α discovery that helper T-cell IL-23 IL-13 IL-15 IFN-β subtype 17 (TH17) immunity Related article page 342 (and related cytokines inter- leukin-17 [IL-17] and IL-23) plays a central role in psoriasis JAK2/TYK2 JAK1/3 JAK1/2 JAK1/TYK2 JAK pathogenesis has led to the development of effective treat- JAK2/TYK2 JAK1/TYK2 JAK1/3 JAK1/TYK2 inhibitor ments with agents targeting IL-17 and IL-23 (eg, secukinumab and guselkumab, respectively). More recently our understand- STAT activation STAT activation STAT activation STAT activation ing of atopic dermatitis pathogenesis has advanced and we now Disease Disease Disease Disease have targeted therapy for this common dermatosis. The cyto- pathogenesis pathogenesis pathogenesis pathogenesis kines IL-4 and IL-13 have been identified as drivers of atopic IL indicates interleukin; JAK, Janus

Journal

JAMA DermatologyAmerican Medical Association

Published: Mar 23, 2019

References